Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the publication of results from a Phase 1/2a study of intrathecal administration of VTS-270, a 2-hydoxypropyl-β-cyclodextrin (HPβCD) under investigation for treatment of Niemann-Pick Disease Type C1 (NPC-1). The results of the study were published in the August 10, 2017 issue of The Lancet and can be found at http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)31465-4.pdf.
{iframe}http://ir.sucampo.com/press-releases/detail/299/study-results-published-in-the-lancet-demonstrate-safety{/iframe}